Immune Issues After Adjuvant Anti –PD-1 Therapy in Melanoma Immune Issues After Adjuvant Anti –PD-1 Therapy in Melanoma

Chronic immune-related adverse events often persist years after adjuvant anti –PD-1 immunotherapy for high-risk melanoma and may require prolonged monitoring and management, researchers say.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news